DUSP22

Across TCGA pan-cancer cohorts, DUSP22 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated DUSP22 data layer compared with 24 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher DUSP22 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated DUSP22 expression acts as an unfavorable survival marker.

ACC, LUAD, and SARC are the cancer types where DUSP22 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.120	0.772	<.001	30	view →
LUAD	DFS	Median	IV	0.045	0.717	<.001	12	view →
SARC	DFS	Median	All	0.190	0.612	.034	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

DUSP22–ACC (DFS)

Open the ACC breakdown →